Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression

Archives of General Psychiatry

Volumn 53, Issue 2, 1996, Pages 137-143

  Purba, Jan S ^a   Hoogendijk, Witte J G ^a,b   Hofman, Michel A ^a   Swaab, Dick F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b Graduate School of Communication   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; OXYTOCIN; VASOPRESSIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; DEPRESSION; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MALE; MORPHOMETRICS; NEUROTRANSMITTER RELEASE; THALAMUS MIDLINE NUCLEUS; TISSUE FIXATION;

EID: 0030032350     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1996.01830020055007     Document Type: Article

References (70)

1. Hofman MA, Swaab DF. Seasonal changes in the suprachiasmatic nucleus of man Neurosci Lett. 1992;139.257-260.
2. Hofman MA, Swaab DF. Diurnal and seasonal rhythms of neuronal activity in the suprachiasmatic nucleus of humans. J Biol Rhythms. 1993;38:163-171.
3. Hofman MA, Purba JS, Swaab DF. Annual variation in the vasopressin neuron population of the human suprachiasmatic nucleus. Neuroscience. 1993;53: 1103-1112.
4. Rosenthal NE, Sack DA, Skwerer RG, Jacobsen FM, Wehr TA. Phototherapy for seasonal affective disorder. J Biol Rhythms. 1988;3:101-120.
5. Wehr TA, Rosenthal NE. Seasonality and affective illness. Am J Psychiatry. 1989,146:829-839.
6. Raadsheer FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF. Increased number of corticotropin-reteasing hormone neurons in the hypothalamic paraventricular nuclei of depressed patients. Neuroendocrinology. 1994;60:436-444
7. Raadsheer FC, Van Heerikhuize JJ, Lucassen PJ, Tilders FJH, Swaab DF. Increased corticotropin-releasing hormone (CRH) mRNA in paraventricular nucleus of patients with Alzheimer's disease or depression. Am J Psychiatry. 1995; 152:1372-1376.
8. Holsboer F, Sprengler D, Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res. 1992;93.385-417.
9. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW. Overproduction of coticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 1994;14:2579-2584.
10. Legros JJ, Ansseau M. Neurohypophyseal peptides and psychopathology. Prog Brain Res. 1992;93.455-461.
11. Legros JJ, Ansseau M, Timsit-Berthier M. Neurohypophyseal peptides and psychiatric disease. Regul Pept. 1993;45:133-138.
12. Jolkkonen J, Tuomisto L, Van Wimetsma Greidanus TjB, Riekkinen PJ. Vasopressin levels in the cerebrospinal fluid of rats with lesions of the paraventricular and suprachiasmatic nuclei Neurosci Lett. 1988;86:184-188.
13. Gash DM, Boer GJ, eds Vasopressin: Principles and Properties. New York, NY: Plenum Press; 1987
14. Cunningham ET Jr, Sawchenko PE Reflex control of magnocellular vasopressin and oxytocin secretion. Trends Neurosci. 1991;14:406-411.
15. Swaab DF, Hofman MA, Lucassen PJ, Purba JS, Raadsheer CF, Van de Nes JAP Functional neuroanatomy and neuropathology of the hypothalamus. Anat Embryol 1993;187:317-330.
16. Buijs RM, Swaab DF, Dogterom J, Van Leeuwen FW. Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Cell Tissue Res. 1978;186:423-433.
17. Fliers E, Swaab DF, Pool CW, Verwer RWH. The vasopressin and oxytocin neurons in the human supraoptic nucleus and paraventricular nucleus with aging and in senile dementia. Brain Res. 1985,342:45-53.
18. Buijs RM The ultra structural localization of amines, amino acids and peptides in the brain. Prog Brain Res 1982;55.167-183.
19. Swanson LW. The hypothalamus. In: Björklund A, Hokfelt T, Swanson LW, eds Handbook of Chemical Neuroanatomy. Amsterdam, the Netherlands. Elsevier Science Publishers, 1987,5:1-124.
20. De Wied D, Versteeg V. Neurohypophyseal principles and memory. Fed Proc. 1979;38:2348-2354.
21. Holsboer-Trachsler E, Stochler R, Hatzinger M. Repeated administration of combined dexamethasone-human corticotropin releasing hormone stimulating test during treatment of depression Psychiatry Res. 1991;38:163-171
22. Callahan MF, Thore CR, Sundberg DK, Gruber KA, O'Steen K, Morris M. Excitotoxin paraventricular nucleus lesions: stress and endocrine reactivity and oxytocin mRNA levels. Brain Res. 1992;597:8-15
23. Bartanusz V, Jezova D, Bertini LT, Tilders FJH, Aubry JM, Kiss J. Stress-induced increase in vasopressin and corticotropin-releasing factor expression in hypophysiotropic paraventricular nucleus. Endocrinology. 1993;132:895-902
24. Legros JJ, Genen V, Linkowski P, Mendelwicz J. Increased neurophysins I and Il cerebrospinal fluid concentration from bipolar versus unipolar depressed patients. Neuroendocrinol Lett 1983;5:201-205.
25. Gjerris A, Hummer M, Vendsborg P, Christiensen NJ, Rafaelson DJ Cerebrospinal fluid vasopressin changes in depression. Br J Psychiatry. 1985;147. 696-701.
26. Laruelle M, Seghers A, Goffinet S, Bonchez S, Legros JJ. Plasmatic vasopressin neurophysin in depression: basic levels and relations with HPA axis. Biol Psychiatry. 1990;27.1249-1261
27. Linkowski P, Genen V, Kerkhofs M, Mendlewicz J, Legros JJ. Cerebrospinal fluid neurophysins in affective illness and schizophrenia. Eur Arch Psychiatry Neurol Sci 1984,234:162-165.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
29. Pool CW, Madlener S, Diegenbach PC, Sluiter AA, Van der Sluis P. Quantification of antiserum reactivity in immunocytochemistry. J Histochem Cytochem. 1984;32 921-928.
30. Wierda M, Goudsmit E, Van der Woude PF, Purba JS, Hofman MA, Swaab DF. Oxytocin cell number in the human paraventricular nucleus remains constant with aging and in Alzneimer's disease. Neurobiol Aging. 1991,12 511-516.
31. Van Eden CG, Uylings HBM, Van Pelt J. Sex-difference and left-right asymmetries in the prefrontal cortex during postnatal development in the rat Dev Brain Res. 1984;12:146-153.
32. Weibel ER. Stereological Methods: Practical Methods for Biological Morphometry. Orlando, Fla: Academic Press Inc; 1979;1:186-196
33. Cruz-Orive LM. Particle shape-size distributions, the general spheroid problem, It: stochastic model and practical guide. J Microsc. 1978;112:153-167.
34. Uylings HBM, Van Eden CG, Hofman MA. Morphometry of size/volume variables and comparison of their bivariate relations in the nervous system under different conditions. J Neurosci Methods. 1986;18:19-37.
35. Fliers E, Guldenaar SEF, Van der Waal N, Swaab DF. Extrahypothalamic vasopressin and oxytocin in the human brain: presence of vasopressin cells in the bed nucleus of the stria terminalis. Brain Res. 1986;375:363-367.
36. Van der Woude PF, Goudsmit E, Wierda M, Purba JS, Hofman MA, Swaab DF. No vasopressin cell loss in the human paraventricular and supraoptic nucleus during aging and in Aizheimer's disease. Neurobiol Aging. 1995;16:11-18.
37. Kalin NH, Dawson G. Neuroendocrine dysfunction in depression: hypothalamicanterior pituitary systems. Trends Neurosci. 1986;9:261-266.
38. Mendels J. Clinical management of the depressed geriatric patient: current therapeutic options. Am J Med. 1993;94:12-18.
39. Judd LL, Craig RS, Parker DC, Janowsky DS, Segal DS, Huey LY Blunted prolactin response. Arch Gen Psychiatry. 1982;39:1413-1416.
40. Rosenthal NE, Levendosky AA, Skwerer RG, Joseph-Vanderpool JR, Kelly KA, Hardin T, Kaspar S, DellaBella P, Wehr TA. Effects of light treatment on core body temperature in seasonal affective disorders. Biol Psychiatry. 1990;27.39-50.
41. Lewy AJ. Treating chronobiologic sleep and mood disorders with bright light. Psychiatry Annu. 1987;17:664-669.
42. Van Someren EJW, Mirmiran M, Swaab DF Non-pharmacological treatment of sleep and wake disturbances in aging and Aizheimer's disease: chronobiological perspectives. Behav Brain Res. 1993;57:235-253.
43. Hoogendijk JE, Fliers E, Swaab DF, Verwer RWH Activation of vasopressin neurons in the human supraoptic and paraventricular nucleus in senescence and senile dementia J Neurol Sci. 1985;69:291-299.
44. Lucassen PJ, Salehi A, Pool CW, Gonatas NK, Swaab DF. Activation of vasopressin neurons in aging and Aizheimer's disease. J Neuroendocrinol. 1994, 6 673-680.
45. Frolkis VV, Golovchenko SF, Medved VI, Frolkis RA. Vasopressin and cardiovascular system in aging. Gerontology. 1982;28:290-302
46. Yates FE, Maran JW. Stimulation and inhibition of adrenocorticotropin release. In: Knobil E, Sawyer WH, eds. Handbook of Physiology. Washington, DC: American Physiology Society, 1974;4(pt 2):367-404.
47. Gillies G, Lowry P. Corticotropin releasing factor may be modulated by vasopressin. Nature. 1979;278.463-464
48. Gillies GE, Linton EA, Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature. 1982;299:355-357
49. Carlson DE, Dornhorst A, Self SM, Robinson AG, Gann DS. Vasopressin-dependent and -independent control of the release of adrenocorticotropin. Endocrinology 1982;110.680-682
50. Vale WJ, Vaughan J, Yamamoto G, Bruhn T, Douglas C, Dalton D, Rivier C, Rivier J. Assay of Corticotropin releasing factor. Methods Enzymol. 1983,103: 565-577
51. Makara GB. The relative importance of hypothalamic neurons containing corticotropin-releasing factor or vasopressin in the regulation of adrenocorticotropic, hormone secretion In Functional Anatomy of the Neuroendocrine Hypothalamus New York, NY: John Wiley & Sons Inc; 1992:43-53.
52. Vandesande F, Dierickx K. Identification of the vasopressin producing and of oxytocin producing neurons in the hypothalamic magnocellular neurosecretory system of the rat. Cell Tissue Res. 1975;164:153-162.
53. Raadsheer FC, Sluiter AA, Ravid R, Tilders FJH, Swaab DF Localization of corticotropin-releasing hormone (CRH) neuron in the paraventricular nucleus of the human hypothalamus: age dependent colocalization with vasopressin. Brain Res. 1993;615:50-62.
54. Sawchenko PE, Swanson LW, Vale WW. Corticotropin-releasing factor: coexpression within distinct subsets of oxytocin-, vasopressin-, and neurotensin-immunoreactive neurons in the hypothalamus of male rat J Neurosci. 1984; 4.1118-1129.
55. Pretel S, Piekut DT. Coexistence of CRF peptide and oxytocin mRNA in the paraventricular nucleus Peptides. 1990;11.621-624.
56. Muir JL, Pfister HP. Influence of exogenously administered oxytocin on the corticosterone and prolactin response to psychological stress. Pharmacol Biochem Behav. 1988;29:699-703.
57. Elkabir DR, Wyatt ME, Vellucci SV, Herbert J. The effects of separate or combined infusions of corticotropin-releasing factor and vasopressin either intraventricularly or into the amygdala on aggressive and investigative behaviour in the rat. Regul Pept 1990;28.199-214.
58. Bardeleben U, Holsboer F. Cortisol response to a combined dexamethasone-human corticotropin-releasing hormone challenge in patients with depression. J Neuroendocrinol. 1989;1:485-488
59. Arletti R, Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci. 1987,41:1725-1730.
60. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995;80:573-579.
61. Faull CM, Rooke P, Baylis PH. The effect of a highly specific serotonine agonist on osmoregulated vasopressin secretion in healthy man. Clin Endocrinol. 1991;35:423-430.
62. Singer I, Rotenberg D, Puschet JB, Franko EA Lithium-induced nephrogenic diabetes insipidus: in vivo and in vitro studies. J Clin Invest 1972;51:1081-1091
63. De Bellis MD, Gold PW, Geracioti Jr TD, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993;150:656-657.
64. Lutz-Bucher B, Koch B. Evidence for a direct inhibitory effect of morphine on the secretion of posterior pituitary hormones. Eur J Pharmacol. 1980;66:375-378.
65. Gibbs DM Dissociation of oxytocin, vasopressin and corticotropin secretion during different types of stress. Life Sci. 1984;35.487-491
66. Olson BR, Drutarosky MD, Stricker EM, Verbalis J. Brain oxytocin receptors mediate corticotropin-releasing hormone-induced anorexia. Am Physiol Soc. 1991;260:R448-R452.
67. Altzuler N, Rosenberg CR, Winkler B, Fuchs AR, Hill PS, Hruby VJ The metabolic effects of oxytocin are mediated by a uterine type of receptor and are inhibited by oxytocin antagonist and by argmine vasopressin in the dog. Life Sci. 1992,50:739-746.
68. Britton DR, Koob GF, River J, Vale W. Intraventricular corticotropin-releasing hormone enhances behavioral effects of novelty Life Sci. 1982,31:363-367.
69. Morley JE, Levine AS. Corticotropin-releasing factor in grooming and ingestive behavior. Life Sci. 1982;31:1459-1464
70. Lucassen PJ, Goudsmit E, Pool CW, Mengod G, Palacios JM, Raadsheer FC, Guldenaar SEF, Swaab DF In situ hybridization for vasopressin mRNA in the human supraoptic and paraventricular nucleus. quantitative aspects of formalinfixed paraffin-embedded tissue sections as compared to cryostat sections J Neurosci Methods. 1995;57:221-230.